显著肝纤维化的非创伤性诊断进展

蔡卫民

显著肝纤维化的非创伤性诊断进展

蔡卫民

浙江大学医学院附属第一医院传染病研究所传染病诊治国家重点实验室

详细信息

中图分类号: R575.2
计量
- 文章访问数: 5596
- HTML全文浏览量: 7
- PDF下载量: 2069
- 被引次数: 0
出版历程
- 出版日期: 2011-07-20

Noninvasive diagnosis of significant liver fibrosis

Cai WeiMin

摘要

摘要: 回顾血清肝纤维化指标的研究历史,介绍几年来肝纤维化非创伤诊断进展。讨论如何去诊断显著性肝纤维化。血清学指标和瞬时弹性图联合应用,有望更好的诊断肝纤维化。
- 肝硬化 /
- 诊断技术,消化系统 /
- 血清学试验
Abstract: The history of studied serum markers of hepatic fibrosis is reviewed.Recent advances in noninvasive diagnosis are introduced and discussions on how to diagnose significant hepatic fibrosis are discussed.Combined application of serologic test and transient elastography is hopeful to improve the diagnostic accuracy.in liver fibrosis.
- liver cirrhosis /
- diagnostic techniques /
- digestive system

HTML全文

参考文献(34)

[1]贾继东, 李海.肝脏纤维化基础和临床研究进展[J].中华肝脏病杂志, 2009, 17 (1) :5-6.

[2] 陆伦根, 曾民德.肝纤维化的非创伤性诊断和评估[J].中华肝脏病杂志, 2008, 16 (3) :164-168.

[3]Guha IN, Rosenberg WM.Noninvasive assessment of liver fibrosis:serum marker, imaging, and other modalities[J].Clin liver Dis, 2008, 12 (4) :883-900.

[4]Manning DS, Afdhal NH.Diagnosis and Quantitation of fibrosis[J].Gastraenterology, 2008, 134 (6) :1670-1681.

[5]蔡卫民.临床肝纤维化学[M].西安, 陕西人民出版社, 2010:98-162.

[6]European Association For the Study of the Liver.EASL ClinicalPractice Guidelines:management of chronic hepatitis B[J].JHepatol, 2009, 50 (2) :227-242.

[7]蔡卫民, 郑敏, 翁红雷, 等.慢性肝炎患者血清纤维化指标的检测及其意义[J].中华内科杂志, 2001, 40 (7) :448-451.

[8]蔡卫民, 陶君, 翁红雷, 等.血清纤维化指标的影响因素分析[J].中华肝脏病杂志, 2003, 11 (1) :23-25.

[9]蔡卫民, 张彬彬, 翁红雷, 等.八项肝纤维化血清标志物比较研究[J].中华肝脏病杂志, 2004, 12 (4) :219-222.

[10]Zeng MD, Lu LG, Mao YM, et al.Prediction of signifilant fibrosis inHBeAg-positive patients with chronic hepatitis B by a noninvasivemodel[J].Hepatology, 2005, 42 (6) :1437-1445.

[11]张文胜, 王宝恩, 王泰龄, 等.慢性乙型肝炎肝纤维化无创性诊断模型的建立[J].中华肝脏病杂志, 2006, 14 (3) :169-173.

[12]郑瑞丹, 周琨, 咸建春, 等.慢性乙型肝炎病毒感染患者肝纤维化非创伤性诊断模型的应用评价[J].肝脏, 2008, 13 (6) :451-455.

[13]Fontana RJ, Goodman ZD, Dienstag JL, et al.Relationship ofserum fibrosis markers with liver fibrosis stage and collagencontent in patients with advanced chronic hepatitis C[J].Hepatology, 2008, 47 (3) :789-798.

[14]Rossi E, Adams L, Prins A, et al.Validation of the Fibro Testbiochemical markers score in assessing liver fibrosis in hepatitis Cpatients[J].Clin Chem, 2003, 49 (2) :450-454.

[15]桂红莲, 谢青, 王晖, 等.Fribro Test-ActiTest对慢性乙型肝炎肝纤维化和炎症的诊断价值[J].中华肝脏病杂志, 2008, 16 (12) :897-901.

[16]Naveau S, Gaude G, Asnacios A, et al.Diagnostic and prognosticvalues of noninvasive biomarkers of fibrosis in patients withalcoholic liver disease[J].Hepatology, 2009, 49 (1) :97-105.

[17]Sebastiani G, Halfon P, Castera L, et al.SAFE biopsy:a validatedmethod for large-scale staging of liver fibrosis in chronic hepatitisC[J].Hepatology, 2009, 49 (6) :1821-1827.

[18]Sebastiani G, Holfan P, Castera L, et al.Effect of prevalence ofliver fibrosis stages in the performance of non-invasive fibrosisbiomarkers in chronic liver diseases (CLDS) :Results of a large-scale, international study[J].Hepatology, 2009, 50 (Suppl 4) :404A.

[19]Gressner OA, Beer N, Jodlowski A, et al.Impact of qualitycontrol accepated inter-laboratory and intreanalytical variabilityon balculated fibrotest/Actitest scores for the non-invasiveassessment of liver fibrosis[J].Hepatology, 2009, 50 (suppl 4) :88A.

[20]Huang H, Shiffman ML, Cheung RC, et al.Identification of twogene variant associated with risk of advanced fibrosis in patiens withchronic hepatitis C[J].Gastroenterology, 2006, 130 (6) :1679-1687.

[21]Huang H, Shiffman ML, friedmen S, et al.A 7 gene signatureidentifies the risk of developing cirrhosis in patients with chronichepatitis C[J].Hepatology, 2007, 46 (2) :297-306.

[22]Marcolongo M, Young B, Dal Pero F, et al.A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patientswith initially mild chroinic hepatitis C[J].Hepatology, 2009, 50 (4) :1038-1044.

[23]Gatti D, Maki A, Chesler EJ, et al.Genome-level analysisof genetic regulation of liver gene expression networks[J].Hepatology, 2007, 46 (2) :548-557.

[24]Zheng M, Cai WM, Zhao JK, et al.Determination of serum levels ofYKL-40 and hyaluronic acid in patients with hepatic fibrosis dueto schistosomiasis japonica and appraisal of their chinical value[J].Acta Trop, 2005, 96 (2-3) :148-152.

[25]Lai KKY, Klippakkam D, Beretta L.Comprehensive and quantitativeproteome profiling of mouse liver and plasma[J].Hepatology, 2008, 47 (3) :1043-1051.

[26]Molleken C, sitek B, Henkel C, et al.Detection of novel biomarkersof liver cirrhosis by proteomic analysis[J].Hepatology, 2009, 49 (4) :1257-1266.

[27]Huwart L, Sempoux C, Vicaut E, et al.Magnetic resonanceelastography for the noninvasive staging of liver fibrosis[J].Gastroenterology, 2008, 135 (1) :32-40.

[28]Lucidarme D, Foucher J, Le Bail B, et al.Factors of accuracy oftransient elastography (fibroscan) for the diagnosis of liver fibrosisin chronic hepatitis C[J].Hepatology, 2009, 49 (4) :1083-1089.

[29]Masuzaki R, Tateishi R, Yoshida H, et al.Prospective riskassessment for hepatocellular carcinoma development in patientswith chronic hepatitis C by transient elastography[J].Hepatology, 2009, 49 (6) :1954-1961.

[30]Carróin JA, Torres F, Crespo G, et al.Liver stiffness idenifies twodifferent patterns of fibrosis progression in patients with hepatitisC Virus recurrence after liver transplantation[J].Hepatology, 2010, 51 (1) :23-34.

[31]Wong VW, Vergniol J, Wong GL, et al.Diagnosis of fibrosis andcirrhosis using liver stiffness measurement in nonalcoholic fattyliver disease[J].Hepatology, 2010, 51 (2) :452-462.

[32]Adams L.Transient elastography in nonalcoholic fatty liver disease:making sense of echos[J].Hepatology, 2010, 51 (2) :370-372.

[33]Castera L, Foucher J, Bernard PH, et al.Pitfalls of liverstiffness measurement:a 5-year prospective study of 13, 369examinations[J].Hepatology, 2010, 51 (3) :828-835.

[34]Fung J, Lai CL, But D, et al.Prevalence of fibrosis and cirrhosis inchronic hepatitis B:implication for treatment and management[J].Am J Gastroenterol, 2008, 103 (6) :1421-1426.

施引文献

资源附件(0)

访问统计